Evidence map›Paper›PMID 28220212›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2017

Rho kinase inhibition ameliorates cyclophosphamide-induced cystitis in rats.

Andrzej Wróbel, Urszula Doboszewska, Ewa Rechberger, Karol Rojek, Anna Serefko, Ewa Poleszak, Krystyna Skalicka-Woźniak, Jarosław Dudka, Piotr Wlaź

Open access · hybridAbstract read
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Andrzej WróbelSecond Department of Gynecology, Medical University of Lublin, Jaczewskiego 8, 20-090, Lublin, Poland. wrobelandrzej@yahoo.com.
Urszula DoboszewskaDepartment of Animal Physiology, Institute of Biology and Biochemistry, Faculty of Biology and Biotechnology, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.
Ewa RechbergerSecond Department of Gynecology, Medical University of Lublin, Jaczewskiego 8, 20-090, Lublin, Poland.
Karol RojekDepartment of Applied Pharmacy, Medical University of Lublin, Chodźki 1, 20-093, Lublin, Poland.
Anna SerefkoDepartment of Applied Pharmacy, Medical University of Lublin, Chodźki 1, 20-093, Lublin, Poland.
Ewa PoleszakDepartment of Applied Pharmacy, Medical University of Lublin, Chodźki 1, 20-093, Lublin, Poland.
Krystyna Skalicka-WoźniakDepartment of Pharmacognosy with Medicinal Plant Unit, Medical University of Lublin, Chodźki 1, 20-093, Lublin, Poland.
Jarosław DudkaDepartment of Toxicology, Medical University of Lublin, Jaczewskiego 8b, 20-093, Lublin, Poland.
Piotr WlaźDepartment of Animal Physiology, Institute of Biology and Biochemistry, Faculty of Biology and Biotechnology, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.
Medical University of Lublin · PLMaria Curie-Skłodowska University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemorrhagic cystitis often develops in patients treated with cyclophosphamide (CYP). Studies have indicated that Rho kinase (ROCK) inhibitors may suppress detrusor overactivity symptoms and possess anti-inflammatory properties. The aim of the present study was to investigate whether inhibition of ROCK reduces cystometric and histopathological changes associated with CYP-induced cystitis. The rats received GSK 269962, a ROCK inhibitor, at a dose of 30 mg/kg daily, or vehicle for 7 days. Then, acute chemical cystitis leading to bladder overactivity was induced by CYP injection (200 mg/kg i.p.). Following CYP injection, cystometric studies with physiological saline were performed. Moreover, bladder edema (by the Evans Blue dye leakage technique) and urothelium thickness were measured. CYP injection resulted in a significant increase in cystometric parameters: basal pressure, threshold pressure, bladder contraction duration, relaxation time, detrusor overactivity index, non-voiding contractions amplitude, and non-voiding contractions frequency as well as increased Evans Blue extravasation into bladder tissue, whereas micturition voiding pressure, voided volume, post-void residual, volume threshold, intercontraction interval, bladder compliance, and volume threshold to elicit non-voiding contractions as well as urothelium thickness were significantly decreased in CYP-injected rats. Administration of GSK 269962 normalized the abovementioned CYP injection-induced changes. Inhibition of ROCK was found to ameliorate CYP-induced detrusor overactivity and bladder inflammation. Our data indicate uroprotective effects following ROCK inhibition, which further suggests that this strategy may become an interesting pharmacological tool to prevent urinary adverse effects in patients treated with chemotherapy using CYP.

Indexed as

AnimalsAntineoplastic Agents, AlkylatingCyclophosphamideCystitisDisease Models, AnimalFemaleHemorrhageImidazolesInflammationOxadiazolesRatsRats, Wistarrho-Associated KinasesUrinary Bladder, OveractiveAntineoplastic Agents, AlkylatingCyclophosphamideImidazolesN-(3-((2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo(4,5-c)pyridin-6-yl)oxy)phenyl)-4-((2-(4-morpholinyl)ethyl)oxy)benzamideOxadiazolesrho-Associated KinasesBladder inflammationCyclophosphamide-induced cystitisCystometryOveractive bladderRho kinase inhibitor

Identifiers

PMID28220212
PMCPMC5411406
OpenAlexW2590481391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.